Etanercept in Sjögren's syndrome: A twelve-week randomized, double-blind, placebo-controlled pilot clinical trial

Vidya Sankar, Michael T. Brennan, Marc R. Kok, Rose Anne Leakan, Janine A. Smith, Joan Manny, Bruce J. Baum, Stanley R. Pillemer

Research output: Contribution to journalArticle

196 Citations (Scopus)

Abstract

Objective. To assess the safety and potential efficacy of etanercept in the treatment of Sjögren's syndrome (SS). Methods. This pilot study was a 12-week randomized, double-blind, placebo-controlled trial of etanercept, with 14 subjects in each group. Patients received 25 mg of etanercept or placebo (vehicle) by twice-weekly subcutaneous injection. Patients met the American-European Consensus Group criteria for SS. The primary outcome required at least 20% improvement from baseline values for at least 2 of the following 3 domains: subjective or objective measures of dry mouth, subjective or objective measures of dry eyes, and IgG level or erythrocyte sedimentation rate (ESR). Results. Of the 14 patients taking etanercept, 11 had primary SS and 3 had SS secondary to rheumatoid arthritis. Baseline measures did not differ between the 2 groups. Three etanercept-treated patients and 1 placebo-treated patient did not complete the trial. Five etanercept-treated patients and 3 placebo-treated patients showed improvement from baseline in the primary outcome variable at 12 weeks, but the difference was not statistically significant. There were no significant differences between the groups for changes in subjective measures of oral or ocular symptoms (by visual analog scale), the IgG level, Schirmer I test result, van Bijsterveld score, or salivary flow. At 12 weeks, the ESR had decreased in the etanercept group compared with baseline (P = 0.004); however, the mean reduction was only 18.6%. Conclusion. We found no evidence to suggest that treatment with etanercept at a dosage of 25 mg twice weekly for 12 weeks was clinically efficacious in SS. A larger trial will be necessary to definitively address the efficacy of etanercept in the treatment of SS.

Original languageEnglish (US)
Pages (from-to)2240-2245
Number of pages6
JournalArthritis and Rheumatism
Volume50
Issue number7
DOIs
StatePublished - Jul 2004

Fingerprint

Controlled Clinical Trials
Placebos
Blood Sedimentation
Immunoglobulin G
Etanercept
Subcutaneous Injections
Visual Analog Scale
Mouth
Rheumatoid Arthritis
Therapeutics
Safety

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Sankar, V., Brennan, M. T., Kok, M. R., Leakan, R. A., Smith, J. A., Manny, J., ... Pillemer, S. R. (2004). Etanercept in Sjögren's syndrome: A twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis and Rheumatism, 50(7), 2240-2245. https://doi.org/10.1002/art.20299

Etanercept in Sjögren's syndrome : A twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. / Sankar, Vidya; Brennan, Michael T.; Kok, Marc R.; Leakan, Rose Anne; Smith, Janine A.; Manny, Joan; Baum, Bruce J.; Pillemer, Stanley R.

In: Arthritis and Rheumatism, Vol. 50, No. 7, 07.2004, p. 2240-2245.

Research output: Contribution to journalArticle

Sankar, V, Brennan, MT, Kok, MR, Leakan, RA, Smith, JA, Manny, J, Baum, BJ & Pillemer, SR 2004, 'Etanercept in Sjögren's syndrome: A twelve-week randomized, double-blind, placebo-controlled pilot clinical trial', Arthritis and Rheumatism, vol. 50, no. 7, pp. 2240-2245. https://doi.org/10.1002/art.20299
Sankar, Vidya ; Brennan, Michael T. ; Kok, Marc R. ; Leakan, Rose Anne ; Smith, Janine A. ; Manny, Joan ; Baum, Bruce J. ; Pillemer, Stanley R. / Etanercept in Sjögren's syndrome : A twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. In: Arthritis and Rheumatism. 2004 ; Vol. 50, No. 7. pp. 2240-2245.
@article{a560d17fae0246c6a749ccbb3dd4985b,
title = "Etanercept in Sj{\"o}gren's syndrome: A twelve-week randomized, double-blind, placebo-controlled pilot clinical trial",
abstract = "Objective. To assess the safety and potential efficacy of etanercept in the treatment of Sj{\"o}gren's syndrome (SS). Methods. This pilot study was a 12-week randomized, double-blind, placebo-controlled trial of etanercept, with 14 subjects in each group. Patients received 25 mg of etanercept or placebo (vehicle) by twice-weekly subcutaneous injection. Patients met the American-European Consensus Group criteria for SS. The primary outcome required at least 20{\%} improvement from baseline values for at least 2 of the following 3 domains: subjective or objective measures of dry mouth, subjective or objective measures of dry eyes, and IgG level or erythrocyte sedimentation rate (ESR). Results. Of the 14 patients taking etanercept, 11 had primary SS and 3 had SS secondary to rheumatoid arthritis. Baseline measures did not differ between the 2 groups. Three etanercept-treated patients and 1 placebo-treated patient did not complete the trial. Five etanercept-treated patients and 3 placebo-treated patients showed improvement from baseline in the primary outcome variable at 12 weeks, but the difference was not statistically significant. There were no significant differences between the groups for changes in subjective measures of oral or ocular symptoms (by visual analog scale), the IgG level, Schirmer I test result, van Bijsterveld score, or salivary flow. At 12 weeks, the ESR had decreased in the etanercept group compared with baseline (P = 0.004); however, the mean reduction was only 18.6{\%}. Conclusion. We found no evidence to suggest that treatment with etanercept at a dosage of 25 mg twice weekly for 12 weeks was clinically efficacious in SS. A larger trial will be necessary to definitively address the efficacy of etanercept in the treatment of SS.",
author = "Vidya Sankar and Brennan, {Michael T.} and Kok, {Marc R.} and Leakan, {Rose Anne} and Smith, {Janine A.} and Joan Manny and Baum, {Bruce J.} and Pillemer, {Stanley R.}",
year = "2004",
month = "7",
doi = "10.1002/art.20299",
language = "English (US)",
volume = "50",
pages = "2240--2245",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "7",

}

TY - JOUR

T1 - Etanercept in Sjögren's syndrome

T2 - A twelve-week randomized, double-blind, placebo-controlled pilot clinical trial

AU - Sankar, Vidya

AU - Brennan, Michael T.

AU - Kok, Marc R.

AU - Leakan, Rose Anne

AU - Smith, Janine A.

AU - Manny, Joan

AU - Baum, Bruce J.

AU - Pillemer, Stanley R.

PY - 2004/7

Y1 - 2004/7

N2 - Objective. To assess the safety and potential efficacy of etanercept in the treatment of Sjögren's syndrome (SS). Methods. This pilot study was a 12-week randomized, double-blind, placebo-controlled trial of etanercept, with 14 subjects in each group. Patients received 25 mg of etanercept or placebo (vehicle) by twice-weekly subcutaneous injection. Patients met the American-European Consensus Group criteria for SS. The primary outcome required at least 20% improvement from baseline values for at least 2 of the following 3 domains: subjective or objective measures of dry mouth, subjective or objective measures of dry eyes, and IgG level or erythrocyte sedimentation rate (ESR). Results. Of the 14 patients taking etanercept, 11 had primary SS and 3 had SS secondary to rheumatoid arthritis. Baseline measures did not differ between the 2 groups. Three etanercept-treated patients and 1 placebo-treated patient did not complete the trial. Five etanercept-treated patients and 3 placebo-treated patients showed improvement from baseline in the primary outcome variable at 12 weeks, but the difference was not statistically significant. There were no significant differences between the groups for changes in subjective measures of oral or ocular symptoms (by visual analog scale), the IgG level, Schirmer I test result, van Bijsterveld score, or salivary flow. At 12 weeks, the ESR had decreased in the etanercept group compared with baseline (P = 0.004); however, the mean reduction was only 18.6%. Conclusion. We found no evidence to suggest that treatment with etanercept at a dosage of 25 mg twice weekly for 12 weeks was clinically efficacious in SS. A larger trial will be necessary to definitively address the efficacy of etanercept in the treatment of SS.

AB - Objective. To assess the safety and potential efficacy of etanercept in the treatment of Sjögren's syndrome (SS). Methods. This pilot study was a 12-week randomized, double-blind, placebo-controlled trial of etanercept, with 14 subjects in each group. Patients received 25 mg of etanercept or placebo (vehicle) by twice-weekly subcutaneous injection. Patients met the American-European Consensus Group criteria for SS. The primary outcome required at least 20% improvement from baseline values for at least 2 of the following 3 domains: subjective or objective measures of dry mouth, subjective or objective measures of dry eyes, and IgG level or erythrocyte sedimentation rate (ESR). Results. Of the 14 patients taking etanercept, 11 had primary SS and 3 had SS secondary to rheumatoid arthritis. Baseline measures did not differ between the 2 groups. Three etanercept-treated patients and 1 placebo-treated patient did not complete the trial. Five etanercept-treated patients and 3 placebo-treated patients showed improvement from baseline in the primary outcome variable at 12 weeks, but the difference was not statistically significant. There were no significant differences between the groups for changes in subjective measures of oral or ocular symptoms (by visual analog scale), the IgG level, Schirmer I test result, van Bijsterveld score, or salivary flow. At 12 weeks, the ESR had decreased in the etanercept group compared with baseline (P = 0.004); however, the mean reduction was only 18.6%. Conclusion. We found no evidence to suggest that treatment with etanercept at a dosage of 25 mg twice weekly for 12 weeks was clinically efficacious in SS. A larger trial will be necessary to definitively address the efficacy of etanercept in the treatment of SS.

UR - http://www.scopus.com/inward/record.url?scp=3142755717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142755717&partnerID=8YFLogxK

U2 - 10.1002/art.20299

DO - 10.1002/art.20299

M3 - Article

C2 - 15248223

AN - SCOPUS:3142755717

VL - 50

SP - 2240

EP - 2245

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 7

ER -